Latest news

89% of adults and 97% of HCPs across the globe believe support for the growing aging population is a key issue for the healthcare industry to address 72% of HCPs believe that data and technology will help reduce burnout and streamline medical training, highlighting the power of AI and technology to increase efficiency Adults worldwide express willingness to share health data in return for personalized treatment plans

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, has potential to become a new standard of care for most common depressive disorders Addition of CAPLYTA® strengthens J&J’s robust lineup of therapies with $5 billion+ potential in peak year salesi, further solidifying sales growth above analyst expectations now through the remainder of the decade Acquisition also includes promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer’s disease-related psychosis and agitation

Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution

SmartfIRE 12-month data demonstrated 86.9% effectiveness when utilized with high adherence to the recommended ablation workflow and significant quality of life improvements using the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter1 Additional real-world evidence from company-funded REAL AF registry shows equivalent outcomes with zero or reduced fluoroscopy versus conventional approaches

Impella heart pump upgraded to Class 2a in ACC/AHA treatment guideline for cardiogenic shock secondary to STEMI